NO991194L - Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride - Google Patents

Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride

Info

Publication number
NO991194L
NO991194L NO991194A NO991194A NO991194L NO 991194 L NO991194 L NO 991194L NO 991194 A NO991194 A NO 991194A NO 991194 A NO991194 A NO 991194A NO 991194 L NO991194 L NO 991194L
Authority
NO
Norway
Prior art keywords
alfa
methoxyimino
azabicyclo
oct
controlled
Prior art date
Application number
NO991194A
Other languages
Norwegian (no)
Other versions
NO991194D0 (en
Inventor
Susan Marie Milosovich
William Muldoon
Joseph Sauer
James Albert Napper
Laurence Rousseau
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO991194L publication Critical patent/NO991194L/en
Publication of NO991194D0 publication Critical patent/NO991194D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Preparat med regulert frigjøring av en acetonitrilforbindelse og dens anvendelse ved behandling og/eller profylakse av visse lidelser.Controlled release preparation of an acetonitrile compound and its use in the treatment and / or prophylaxis of certain disorders.

NO991194A 1996-09-12 1999-03-11 Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride NO991194D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (2)

Publication Number Publication Date
NO991194L true NO991194L (en) 1999-03-11
NO991194D0 NO991194D0 (en) 1999-03-11

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991194A NO991194D0 (en) 1996-09-12 1999-03-11 Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride

Country Status (22)

Country Link
EP (1) EP0929301A2 (en)
JP (1) JP2001500150A (en)
KR (1) KR20000036039A (en)
CN (2) CN1235544A (en)
AR (1) AR008176A1 (en)
AU (1) AU724086B2 (en)
BR (1) BR9711734A (en)
CA (1) CA2265661A1 (en)
CO (1) CO5031291A1 (en)
CZ (1) CZ83299A3 (en)
GB (1) GB9619074D0 (en)
HU (1) HUP9904401A3 (en)
ID (1) ID19589A (en)
IL (1) IL128781A0 (en)
MA (1) MA24359A1 (en)
NO (1) NO991194D0 (en)
NZ (1) NZ334268A (en)
PE (1) PE2499A1 (en)
PL (1) PL332074A1 (en)
TR (1) TR199900505T2 (en)
WO (1) WO1998010762A2 (en)
ZA (1) ZA978133B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (en) * 1998-03-04 2001-04-20 Gattefosse Ets Sa ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
CN1292696A (en) 1998-03-11 2001-04-25 史密丝克莱恩比彻姆有限公司 Composition
DE19918325A1 (en) * 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US8679533B2 (en) 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
US20060252820A1 (en) * 2003-04-25 2006-11-09 Tetsuya Suzuki Composition for oral administration containing alkylene dioxybenzene derivative
DE602004002405T3 (en) * 2003-05-14 2013-06-20 Aptalis Pharma Limited CONTROLLED MEDICATION RELEASE COMPOSITION WITH IN VIVO MECHANICAL RESISTANCE
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk Method for producing solid preparation
WO2006015943A2 (en) 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP2345407A1 (en) 2004-08-13 2011-07-20 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (en) * 1989-04-13 2004-10-18 Beecham Group Plc Hitherto unknown compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (en) * 1995-07-29 1998-11-04 Smithkline Beecham Plc PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.

Also Published As

Publication number Publication date
CA2265661A1 (en) 1998-03-19
CO5031291A1 (en) 2001-04-27
NO991194D0 (en) 1999-03-11
HUP9904401A3 (en) 2001-03-28
CN1235544A (en) 1999-11-17
ID19589A (en) 1998-07-23
KR20000036039A (en) 2000-06-26
WO1998010762A3 (en) 1998-06-04
PE2499A1 (en) 1999-03-24
WO1998010762A2 (en) 1998-03-19
CZ83299A3 (en) 1999-08-11
ZA978133B (en) 1999-04-12
JP2001500150A (en) 2001-01-09
BR9711734A (en) 1999-08-24
TR199900505T2 (en) 1999-06-21
CN1446535A (en) 2003-10-08
GB9619074D0 (en) 1996-10-23
MA24359A1 (en) 1998-07-01
HUP9904401A2 (en) 2000-06-28
IL128781A0 (en) 2000-01-31
PL332074A1 (en) 1999-08-30
AU724086B2 (en) 2000-09-14
NZ334268A (en) 2000-10-27
EP0929301A2 (en) 1999-07-21
AR008176A1 (en) 1999-12-09
AU4128897A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
NO991194L (en) Controlled-release dosage form of [R- (Z) - &lt;alfa&gt; - (methoxyimino) - &lt;alfa&gt; - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride
KR100246065B1 (en) Substituted 3-aminoquinuclidines
NO995794D0 (en) Pharmaceutical preparation containing &#34;Lactobacillus casei rhamnosus&#34;
EP0497258A3 (en) Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer
EE04854B1 (en) Oxabispidine Compounds, Methods and Formulations thereof for use in the treatment and prophylaxis of cardiac arrhythmias
NO864336L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE N-SUBSTITUTED-N- (3- (1,2,4-TRIAZOLO (4,3-6) PYRIDAZIN-6-YL) PHENYL) ALKANAMIDS, CARBAMATES AND URINENTS.
DE69713151D1 (en) CYCLOSPORINE DERIVATIVE, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION
BG103474A (en) Application of derivatives of 7-(2-oxa-5,8-diazobicyclo[4,3,0]non-8-8-yl)-quinoloncarboxylic acid and naphthyridoncarboxylic acid in the therapy of helicobacter pylor infections and the gastroduodenal diseases related to them
ZA941530B (en) Use of lamotrigine in the treatment of neuro-AIDS
NO922426D0 (en) RELATIONSHIPS WITH CLEANING-INHIBITING PROPERTIES, PROCEDURE FOR THE PREPARATION OF THESE AND THEIR USE
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
NO304384B1 (en) Al-Sr-Si-B alloy, process for its preparation and use of the alloy
EE200300504A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
NO983177L (en) Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
MXPA02006146A (en) Methods for treating psychological disorders using bioactive metabolites of gepirone.
GB9203483D0 (en) Anti-inflammatory compounds
EE200300495A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
EE200300506A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
NO910372L (en) PROCEDURE FOR THE PREPARATION OF HEXA HYDROPYRROLO (2,3-B) INDOLCARBAMATER, UREA, AMIDES AND RELATED COMPOUNDS AND THEIR USE AS MEDICINES.
TR199900141T2 (en) Formulation for the treatment and/or prophylaxis of dementia.
ZA931099B (en) Heterocyclic compounds their use and preparation
NO943101L (en) 2,6-methano-2H-quinolizine derivative as a 5-HT 3 receptor antagonist
WO1999015160A3 (en) Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies
PE128999A1 (en) 1,2,4-TRIAZOLO [3,4-A] SUBSTITUTED PIRIDAZINE